CA2688312A1 - Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment - Google Patents
Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment Download PDFInfo
- Publication number
- CA2688312A1 CA2688312A1 CA002688312A CA2688312A CA2688312A1 CA 2688312 A1 CA2688312 A1 CA 2688312A1 CA 002688312 A CA002688312 A CA 002688312A CA 2688312 A CA2688312 A CA 2688312A CA 2688312 A1 CA2688312 A1 CA 2688312A1
- Authority
- CA
- Canada
- Prior art keywords
- breast cancer
- allele
- markers
- individual
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 455
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 454
- 230000002068 genetic effect Effects 0.000 title claims abstract description 121
- 238000004393 prognosis Methods 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 title claims description 67
- 238000003745 diagnosis Methods 0.000 title claims description 32
- 238000012502 risk assessment Methods 0.000 title claims description 19
- 238000000034 method Methods 0.000 claims abstract description 208
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 84
- 201000010099 disease Diseases 0.000 claims abstract description 82
- 230000003247 decreasing effect Effects 0.000 claims abstract description 35
- 230000004044 response Effects 0.000 claims abstract description 24
- 108700028369 Alleles Proteins 0.000 claims description 322
- 239000003550 marker Substances 0.000 claims description 275
- 239000000523 sample Substances 0.000 claims description 228
- 102000054766 genetic haplotypes Human genes 0.000 claims description 221
- 150000007523 nucleic acids Chemical class 0.000 claims description 171
- 102000039446 nucleic acids Human genes 0.000 claims description 158
- 108020004707 nucleic acids Proteins 0.000 claims description 158
- 239000002773 nucleotide Substances 0.000 claims description 114
- 125000003729 nucleotide group Chemical group 0.000 claims description 114
- 206010028980 Neoplasm Diseases 0.000 claims description 101
- 108020004414 DNA Proteins 0.000 claims description 77
- 238000001514 detection method Methods 0.000 claims description 67
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 48
- 238000004458 analytical method Methods 0.000 claims description 48
- 239000002751 oligonucleotide probe Substances 0.000 claims description 48
- 108091034117 Oligonucleotide Proteins 0.000 claims description 43
- 230000035772 mutation Effects 0.000 claims description 42
- 238000003556 assay Methods 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 34
- 238000003205 genotyping method Methods 0.000 claims description 34
- 238000009396 hybridization Methods 0.000 claims description 34
- 230000000295 complement effect Effects 0.000 claims description 31
- 239000003623 enhancer Substances 0.000 claims description 28
- 239000012634 fragment Substances 0.000 claims description 27
- 239000003153 chemical reaction reagent Substances 0.000 claims description 26
- 102000036365 BRCA1 Human genes 0.000 claims description 22
- 108700020463 BRCA1 Proteins 0.000 claims description 22
- 101150072950 BRCA1 gene Proteins 0.000 claims description 22
- 101150008921 Brca2 gene Proteins 0.000 claims description 21
- 102000052609 BRCA2 Human genes 0.000 claims description 20
- 108700020462 BRCA2 Proteins 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 239000013068 control sample Substances 0.000 claims description 17
- 238000003752 polymerase chain reaction Methods 0.000 claims description 15
- 108010042407 Endonucleases Proteins 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- 230000003321 amplification Effects 0.000 claims description 9
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 9
- 230000007423 decrease Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 239000012830 cancer therapeutic Substances 0.000 claims description 6
- 238000012775 microarray technology Methods 0.000 claims description 6
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 230000004224 protection Effects 0.000 claims description 5
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 4
- 238000011325 biochemical measurement Methods 0.000 claims description 4
- 238000010791 quenching Methods 0.000 claims description 4
- 230000000171 quenching effect Effects 0.000 claims description 4
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 claims description 3
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 108010010677 Phosphodiesterase I Proteins 0.000 claims description 2
- 201000007283 progesterone-receptor positive breast cancer Diseases 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims 3
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 description 139
- 102210006768 rs7716600 Human genes 0.000 description 128
- 229920001184 polypeptide Polymers 0.000 description 70
- 102000004196 processed proteins & peptides Human genes 0.000 description 70
- 108090000765 processed proteins & peptides Proteins 0.000 description 70
- 230000014509 gene expression Effects 0.000 description 63
- 229910052760 oxygen Inorganic materials 0.000 description 62
- 201000011510 cancer Diseases 0.000 description 53
- 210000000349 chromosome Anatomy 0.000 description 53
- 238000012360 testing method Methods 0.000 description 49
- 102000004169 proteins and genes Human genes 0.000 description 47
- 230000006798 recombination Effects 0.000 description 31
- 238000005215 recombination Methods 0.000 description 31
- 239000000969 carrier Substances 0.000 description 29
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 28
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 28
- 238000012216 screening Methods 0.000 description 28
- 239000013615 primer Substances 0.000 description 27
- 101000689854 Homo sapiens 39S ribosomal protein S30, mitochondrial Proteins 0.000 description 26
- 102000015694 estrogen receptors Human genes 0.000 description 26
- 108010038795 estrogen receptors Proteins 0.000 description 26
- 102100024420 39S ribosomal protein S30, mitochondrial Human genes 0.000 description 25
- 102000054765 polymorphisms of proteins Human genes 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 19
- 229940079593 drug Drugs 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 238000001959 radiotherapy Methods 0.000 description 18
- 108091092878 Microsatellite Proteins 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 210000000481 breast Anatomy 0.000 description 16
- 230000002596 correlated effect Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 102000003998 progesterone receptors Human genes 0.000 description 16
- 108090000468 progesterone receptors Proteins 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 230000010076 replication Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 14
- 230000004075 alteration Effects 0.000 description 14
- 230000000875 corresponding effect Effects 0.000 description 14
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 101001009074 Homo sapiens Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Proteins 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000004055 small Interfering RNA Substances 0.000 description 12
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 11
- 102100027376 Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 Human genes 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 239000002853 nucleic acid probe Substances 0.000 description 11
- 238000001356 surgical procedure Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000012217 deletion Methods 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000002987 primer (paints) Substances 0.000 description 10
- 229960001603 tamoxifen Drugs 0.000 description 10
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 9
- 230000002113 chemopreventative effect Effects 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 8
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 8
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 8
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 8
- 108091093037 Peptide nucleic acid Proteins 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 201000005389 breast carcinoma in situ Diseases 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000012937 correction Methods 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 8
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 201000011059 lobular neoplasia Diseases 0.000 description 8
- 238000010561 standard procedure Methods 0.000 description 8
- 102220632806 39S ribosomal protein S30, mitochondrial_C33S_mutation Human genes 0.000 description 7
- 102100031780 Endonuclease Human genes 0.000 description 7
- 101150099234 FGF10 gene Proteins 0.000 description 7
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 7
- 210000004408 hybridoma Anatomy 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 7
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011277 treatment modality Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 108091027967 Small hairpin RNA Proteins 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 230000007115 recruitment Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000007726 management method Methods 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 210000004940 nucleus Anatomy 0.000 description 5
- 230000000069 prophylactic effect Effects 0.000 description 5
- 230000008439 repair process Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000033640 Hereditary breast cancer Diseases 0.000 description 4
- 101150070149 MRPS30 gene Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108700020796 Oncogene Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 238000011226 adjuvant chemotherapy Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000012098 association analyses Methods 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000002759 chromosomal effect Effects 0.000 description 4
- 238000013500 data storage Methods 0.000 description 4
- 238000003197 gene knockdown Methods 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 208000025581 hereditary breast carcinoma Diseases 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000030776 invasive breast carcinoma Diseases 0.000 description 4
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 238000009607 mammography Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 238000002966 oligonucleotide array Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000009862 primary prevention Effects 0.000 description 4
- 229960004622 raloxifene Drugs 0.000 description 4
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102210060100 rs16902086 Human genes 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000000528 statistical test Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000013517 stratification Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 108700010154 BRCA2 Genes Proteins 0.000 description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 3
- 238000000729 Fisher's exact test Methods 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 3
- KUGRPPRAQNPSQD-UHFFFAOYSA-N OOOOO Chemical compound OOOOO KUGRPPRAQNPSQD-UHFFFAOYSA-N 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 101150088071 fgfr2 gene Proteins 0.000 description 3
- 230000037433 frameshift Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 238000012252 genetic analysis Methods 0.000 description 3
- 230000009395 genetic defect Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000000491 multivariate analysis Methods 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 238000013439 planning Methods 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000009863 secondary prevention Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 2
- 208000035657 Abasia Diseases 0.000 description 2
- 241000722946 Acanthocybium solandri Species 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 108700040618 BRCA1 Genes Proteins 0.000 description 2
- 101150064168 CHEK2 gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 101150102932 HCN1 gene Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101100220617 Homo sapiens CHEK2 gene Proteins 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091092919 Minisatellite Proteins 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 108020004485 Nonsense Codon Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000003886 aromatase inhibitor Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000003209 gene knockout Methods 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002743 insertional mutagenesis Methods 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 108010029560 keratinocyte growth factor receptor Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 210000004708 ribosome subunit Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 238000011895 specific detection Methods 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- -1 14 (TK14) Proteins 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical group NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- 102000000872 ATM Human genes 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023043 Alu Element Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 101710092097 Apoptosis regulator ced-9 Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100191129 Arabidopsis thaliana LOI1 gene Proteins 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 229940122815 Aromatase inhibitor Drugs 0.000 description 1
- 108010004586 Ataxia Telangiectasia Mutated Proteins Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010006253 Breast fibrosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102100024263 CD160 antigen Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000016216 Choristoma Diseases 0.000 description 1
- 244000175448 Citrus madurensis Species 0.000 description 1
- 235000004332 Citrus madurensis Nutrition 0.000 description 1
- 235000007438 Citrus mitis Nutrition 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000036493 Contralateral breast cancer Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 101150029237 Il11 gene Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 description 1
- 238000003657 Likelihood-ratio test Methods 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 241000997826 Melanocetus johnsonii Species 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 1
- 101100348848 Mus musculus Notch4 gene Proteins 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 101000941356 Nostoc ellipsosporum Cyanovirin-N Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
- 235000011464 Pachycereus pringlei Nutrition 0.000 description 1
- 240000006939 Pachycereus weberi Species 0.000 description 1
- 235000011466 Pachycereus weberi Nutrition 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000030555 Pygmy Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 208000033722 Rare malignant breast tumor Diseases 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- DUDJTRNGXIUJEB-UHFFFAOYSA-N [N].NCC(O)=O Chemical group [N].NCC(O)=O DUDJTRNGXIUJEB-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000017075 cellular response to radiation Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 230000012361 double-strand break repair Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 108010091897 factor V Leiden Proteins 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002243 furanoses Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000013198 immunometric assay Methods 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000011454 long-term hormonal therapy Methods 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 201000003175 male breast cancer Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000016044 mixed lobular and ductal breast carcinoma Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 238000007826 nucleic acid assay Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000000177 oncogenetic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000013058 risk prediction model Methods 0.000 description 1
- 102210023989 rs1078806 Human genes 0.000 description 1
- 102210026013 rs11200014 Human genes 0.000 description 1
- 102210010670 rs13180087 Human genes 0.000 description 1
- 102220429669 rs2420946 Human genes 0.000 description 1
- 102200081254 rs28997576 Human genes 0.000 description 1
- 102210018273 rs2912774 Human genes 0.000 description 1
- 102210010852 rs2912780 Human genes 0.000 description 1
- 102210019473 rs2981578 Human genes 0.000 description 1
- 102210008683 rs2981579 Human genes 0.000 description 1
- 102210020283 rs3750817 Human genes 0.000 description 1
- 102210031283 rs9292918 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011270 sentinel node biopsy Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000009752 translational inhibition Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8647 | 2007-05-25 | ||
| IS8647 | 2007-05-25 | ||
| IS8700 | 2007-12-21 | ||
| IS8700 | 2007-12-21 | ||
| PCT/IS2008/000012 WO2008146309A2 (en) | 2007-05-25 | 2008-05-21 | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2688312A1 true CA2688312A1 (en) | 2008-12-04 |
Family
ID=39661451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002688312A Abandoned CA2688312A1 (en) | 2007-05-25 | 2008-05-21 | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8580501B2 (enExample) |
| EP (2) | EP2535425A1 (enExample) |
| JP (1) | JP2010527603A (enExample) |
| KR (1) | KR20100017865A (enExample) |
| CN (1) | CN101772578A (enExample) |
| AU (1) | AU2008256219B2 (enExample) |
| CA (1) | CA2688312A1 (enExample) |
| EA (1) | EA018444B1 (enExample) |
| IL (1) | IL202292A0 (enExample) |
| MX (1) | MX2009012722A (enExample) |
| NZ (1) | NZ581858A (enExample) |
| WO (1) | WO2008146309A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2463388B1 (en) | 2005-11-29 | 2017-11-22 | Cambridge Enterprise Limited | Markers for breast cancer |
| CN101772578A (zh) * | 2007-05-25 | 2010-07-07 | 解码遗传学私营有限责任公司 | 作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体 |
| CN102144036B (zh) | 2008-07-07 | 2014-07-16 | 解码遗传学私营有限责任公司 | 用于乳腺癌风险评估的遗传变型 |
| GB2466025A (en) * | 2008-12-08 | 2010-06-09 | Univ Francois Rabelais De Tour | C3/ITGAM polymorphisms and cancer prognosis |
| EP2438193B1 (en) * | 2009-06-01 | 2015-07-22 | Genetic Technologies Limited | Methods for breast cancer risk assessment |
| WO2011006214A1 (en) * | 2009-07-16 | 2011-01-20 | Peter Maccallum Cancer Institute | Method of detecting radiation exposure and adverse toxicity thereto |
| US20110151457A1 (en) * | 2009-12-22 | 2011-06-23 | Elitech Holding B.V. | Hypertheromostable endonuclease iv substrate probe |
| WO2011095999A1 (en) * | 2010-02-05 | 2011-08-11 | Decode Genetics Ehf | Genetic variants for predicting risk of breast cancer |
| JP6420543B2 (ja) * | 2011-01-19 | 2018-11-07 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | ゲノムデータ処理方法 |
| US20140329719A1 (en) * | 2011-06-16 | 2014-11-06 | Illumina, Inc. | Genetic variants for predicting risk of breast cancer |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| WO2014160876A2 (en) * | 2013-03-27 | 2014-10-02 | Memorial Sloan-Kettering Cancer Center | Brca2-specific modifier locus related to breast cancer risk |
| KR101748867B1 (ko) * | 2013-04-19 | 2017-06-20 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 자동화 시스템 |
| WO2015035415A1 (en) | 2013-09-09 | 2015-03-12 | Nantomics, Llc | Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes |
| CN103966310A (zh) * | 2014-01-27 | 2014-08-06 | 广州市体育科学研究所 | 乳腺癌易感基因快速检测试剂盒及检测方法 |
| CN104232774A (zh) * | 2014-09-17 | 2014-12-24 | 湖北维达健基因技术有限公司 | 用于检测乳腺癌易感基因snp的引物、荧光探针及应用 |
| EP3201360A4 (en) | 2014-09-30 | 2018-05-09 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| CN107250356A (zh) * | 2014-12-16 | 2017-10-13 | 加文医学研究所 | 测序对照 |
| ES2908347T3 (es) | 2015-02-10 | 2022-04-28 | Univ Hong Kong Chinese | Detección de mutaciones para cribado de cáncer y análisis fetal |
| CN106295241A (zh) * | 2015-06-25 | 2017-01-04 | 杭州圣庭生物技术有限公司 | 基于brca1和brca2突变的乳腺癌患病风险评估算法 |
| EP4279612B1 (en) | 2015-07-23 | 2025-07-02 | The Chinese University of Hong Kong | Analysis of fragmentation patterns of cell-free dna |
| CN105586427B (zh) * | 2016-03-10 | 2020-06-19 | 厦门艾德生物医药科技股份有限公司 | 检测人类brca1和brca2基因突变的引物、试剂盒及方法 |
| CN107723350A (zh) * | 2016-08-12 | 2018-02-23 | 嘉兴允英医学检验有限公司 | 一种遗传性乳腺癌突变基因高通量筛查方法 |
| AU2018212272B2 (en) | 2017-01-25 | 2022-04-28 | Grail, Inc. | Diagnostic applications using nucleic acid fragments |
| CN111051536A (zh) | 2017-07-26 | 2020-04-21 | 香港中文大学 | 利用不含细胞的病毒核酸改善癌症筛选 |
| CN107254545B (zh) * | 2017-08-16 | 2020-09-15 | 复旦大学附属华山医院北院 | 一种与乳腺癌化疗毒性相关的snp标志物及其应用 |
| CN107254546B (zh) * | 2017-08-16 | 2020-11-03 | 复旦大学附属华山医院 | 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用 |
| CN107729241B (zh) * | 2017-10-12 | 2020-11-03 | 中国矿业大学 | 一种基于变异体分组的软件变异测试数据进化生成方法 |
| KR101985864B1 (ko) * | 2017-12-28 | 2019-06-05 | 주식회사 엔젠바이오 | 유방암 및 난소암 등 암 진단용 조성물 및 이의 용도 |
| CN109913550A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 乳腺癌新辅助化疗效果预测基因试剂盒 |
| RU2702755C1 (ru) * | 2019-06-24 | 2019-10-11 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Способ молекулярно-генетической диагностики наследственных форм рака молочной железы |
| CN110358834B (zh) * | 2019-07-12 | 2023-05-16 | 深圳大学 | 一种lncRNA的应用以及试剂盒和药物 |
| CN112837749B (zh) * | 2021-02-01 | 2021-11-26 | 北京百奥纳芯生物科技有限公司 | 一种癌症筛查用基因芯片探针的优选方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| DE69527585T2 (de) | 1994-06-08 | 2003-04-03 | Affymetrix, Inc. | Verfahren und Vorrichtung zum Verpacken von Chips |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| WO1997045559A1 (en) | 1996-05-29 | 1997-12-04 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| IL163645A0 (en) * | 2002-02-21 | 2005-12-18 | Idgene Pharmaceuticals Ltd | Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer |
| AU2003276973A1 (en) * | 2002-09-25 | 2004-04-19 | Amersham Biosciences (Sv) Corp. | Detection methods |
| CA2505786C (en) * | 2002-11-25 | 2011-06-21 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| KR101138862B1 (ko) * | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
| KR101206028B1 (ko) * | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
| US7858303B2 (en) * | 2005-03-14 | 2010-12-28 | Wisconsin Alumni Research Foundation | Method of analyzing breast cancer susceptibility and resistance |
| MX2007014447A (es) * | 2005-05-18 | 2008-04-16 | Decode Genetics Ehf | Variantes en cromosoma 8q24.21 que confieren riesgo de cancer. |
| US20070092900A1 (en) * | 2005-10-26 | 2007-04-26 | Stacey Simon N | Methods for diagnosing and characterizing breast cancer and susceptibility to breast cancer |
| CN101772578A (zh) * | 2007-05-25 | 2010-07-07 | 解码遗传学私营有限责任公司 | 作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体 |
-
2008
- 2008-05-21 CN CN200880100074A patent/CN101772578A/zh active Pending
- 2008-05-21 EA EA200971079A patent/EA018444B1/ru not_active IP Right Cessation
- 2008-05-21 MX MX2009012722A patent/MX2009012722A/es active IP Right Grant
- 2008-05-21 CA CA002688312A patent/CA2688312A1/en not_active Abandoned
- 2008-05-21 WO PCT/IS2008/000012 patent/WO2008146309A2/en not_active Ceased
- 2008-05-21 US US12/303,238 patent/US8580501B2/en not_active Expired - Fee Related
- 2008-05-21 JP JP2010508970A patent/JP2010527603A/ja active Pending
- 2008-05-21 KR KR1020097026476A patent/KR20100017865A/ko not_active Ceased
- 2008-05-21 EP EP12163654A patent/EP2535425A1/en not_active Withdrawn
- 2008-05-21 EP EP08763758A patent/EP2164984A2/en not_active Withdrawn
- 2008-05-21 AU AU2008256219A patent/AU2008256219B2/en not_active Ceased
- 2008-05-21 NZ NZ581858A patent/NZ581858A/en not_active IP Right Cessation
-
2009
- 2009-11-23 IL IL202292A patent/IL202292A0/en unknown
-
2013
- 2013-10-09 US US14/050,052 patent/US20140179546A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8580501B2 (en) | 2013-11-12 |
| KR20100017865A (ko) | 2010-02-16 |
| AU2008256219B2 (en) | 2014-06-05 |
| JP2010527603A (ja) | 2010-08-19 |
| AU2008256219A1 (en) | 2008-12-04 |
| EP2164984A2 (en) | 2010-03-24 |
| WO2008146309A2 (en) | 2008-12-04 |
| EA018444B1 (ru) | 2013-08-30 |
| EP2535425A1 (en) | 2012-12-19 |
| CN101772578A (zh) | 2010-07-07 |
| US20110015081A1 (en) | 2011-01-20 |
| EA200971079A1 (ru) | 2010-06-30 |
| WO2008146309A3 (en) | 2009-01-22 |
| US20140179546A1 (en) | 2014-06-26 |
| IL202292A0 (en) | 2010-06-16 |
| MX2009012722A (es) | 2009-12-11 |
| NZ581858A (en) | 2012-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8580501B2 (en) | Genetic variants on chr 5p12 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| US8951735B2 (en) | Genetic variants for breast cancer risk assessment | |
| US20110117545A1 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| US8865400B2 (en) | Genetic variants contributing to risk of prostate cancer | |
| CA2729931A1 (en) | Genetic variants predictive of cancer risk in humans | |
| NZ576591A (en) | Cancer susceptibility variants on chr8q24.21 | |
| US20110020320A1 (en) | Genetic Variants Contributing to Risk of Prostate Cancer | |
| US20110091880A1 (en) | Susceptibility variants for lung cancer | |
| US20140248615A1 (en) | Genetic variants on chr 11q and 6q as markers for prostate and colorectal cancer predisposition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130509 |
|
| FZDE | Discontinued |
Effective date: 20160524 |